Human IL-1 Rrp2 / IL-1 R6 Protein, His Tag
分子別名(Synonym)
IL-1 R6,IL-1 Rrp2,IL1RL2,IL-1RL2,IL1Rrp2,IL-1Rrp2,IL1RRP2,IL-36R
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human IL-1 Rrp2, His Tag (IL2-H52H6) is expressed from human 293 cells (HEK293). It contains AA Asp 20 - Arg 335 (Accession # Q9HB29-1).
Predicted N-terminus: Asp 20
蛋白結(jié)構(gòu)(Molecular Characterization)

This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 37.8 kDa. The protein migrates as 55-66 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method / rFC method.
純度(Purity)
>90% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景介紹
白細(xì)胞介素-1受體家族(IL-1 R)至少包含11個(gè)成員,包括IL-1 RI(IL-1 R1)、IL-1 RII(IL-1 R2)、IL-1 RAcP(IL1 R3)、ST2(T1/IL-1 R4)、IL-18 Ra(IL-1 Rrp/IL-1 R5)、IL-1 Rrp2(IL-1 RL2/IL-1 R6)、IL-18 Rb(AcPL/IL-1 R7)、IL-1RAPL1(TIGIRR2/IL1 R8)和TIGIRR-1(IL-1 R9)。所有家族成員的胞外區(qū)均包含三個(gè)免疫球蛋白(Ig)樣結(jié)構(gòu)域。大多數(shù)成員還擁有一個(gè)胞內(nèi)TIR(Toll樣受體/IL-1受體信號轉(zhuǎn)導(dǎo))結(jié)構(gòu)域,該結(jié)構(gòu)域在Toll樣受體家族中也高度保守。相關(guān)蛋白SIGIRR(含單個(gè)Ig結(jié)構(gòu)域的IL-1 R相關(guān)分子)和IL-18BP與其他成員不同,僅含有一個(gè)Ig結(jié)構(gòu)域。
關(guān)鍵字: IL-1 Rrp2;IL-1 Rrp2蛋白;IL-1 Rrp2重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。